Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.745 USD | +7.99% | +1.86% | -43.09% |
09/05 | Barclays Adjusts Editas Medicine Price Target to $9 From $11, Maintains Equal Weight Rating | MT |
09/05 | Morgan Stanley Upgrades Editas Medicine to Equal-Weight From Underweight | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-43.09% | 438M | |
+26.74% | 44.96B | |
+0.24% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+10.22% | 26.08B | |
-21.20% | 19.03B | |
+6.67% | 12.75B | |
+28.79% | 12.06B | |
-3.93% | 11.75B |
- Stock Market
- Equities
- EDIT Stock
- News Editas Medicine, Inc.
- Truist Adjusts Editas Medicine's Price Target to $20 From $15, Maintains Buy Rating